# Powell Industries Inc: financial statements, quarterly

POWL · Nasdaq · CIK 80420 · [Technology](/sectors/technology.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/powl.md) · [Financials](/companies/powl/financials.md) · [Filings](/companies/powl/filings.md) · [Insiders](/companies/powl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/powl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [209](/filings/0000080420-24-000086.md) | [194](/filings/0000080420-25-000029.md) | [255](/filings/0000080420-25-000061.md) | [288](/filings/0000080420-25-000098.md) | [275](/filings/0000080420-25-000152.md) | [241](/filings/0000080420-26-000015.md) | [279](/filings/0000080420-26-000070.md) | [286](/filings/0000080420-26-000107.md) | [298](/filings/0000080420-25-000152.md) | [251](/filings/0000080420-26-000015.md) | [297](/filings/0000080420-26-000070.md) | [312](/filings/0000080420-26-000107.md) |
| Cost of revenue | $m | [157 d](/filings/0000080420-25-000152.md) | [146](/filings/0000080420-25-000029.md) | [192](/filings/0000080420-25-000061.md) | [206](/filings/0000080420-25-000098.md) | [195 d](/filings/0000080420-25-000152.md) | [182](/filings/0000080420-26-000015.md) | [195](/filings/0000080420-26-000070.md) | [198](/filings/0000080420-26-000107.md) | [204 d](/filings/0000080420-25-000152.md) | [180](/filings/0000080420-26-000015.md) | [209](/filings/0000080420-26-000070.md) | [216](/filings/0000080420-26-000107.md) |
| Gross profit | $m | [52.0](/filings/0000080420-24-000086.md) | [48.2](/filings/0000080420-25-000152.md) | [62.7](/filings/0000080420-25-000152.md) | [81.7](/filings/0000080420-25-000152.md) | [80.4](/filings/0000080420-25-000152.md) | [59.5](/filings/0000080420-26-000015.md) | [83.4](/filings/0000080420-26-000070.md) | [87.9](/filings/0000080420-26-000107.md) | [93.5](/filings/0000080420-25-000152.md) | [71.4](/filings/0000080420-26-000015.md) | [87.9](/filings/0000080420-26-000070.md) | [95.3](/filings/0000080420-26-000107.md) |
| Research and development | $m | [1.7 d](/filings/0000080420-25-000152.md) | [2.0](/filings/0000080420-25-000029.md) | [2.3](/filings/0000080420-25-000061.md) | [2.4](/filings/0000080420-25-000098.md) | [2.7 d](/filings/0000080420-25-000152.md) | [2.5](/filings/0000080420-26-000015.md) | [2.7](/filings/0000080420-26-000070.md) | [2.7](/filings/0000080420-26-000107.md) | [3.1 d](/filings/0000080420-25-000152.md) | [3.3](/filings/0000080420-26-000015.md) | [4.3](/filings/0000080420-26-000070.md) | [4.3](/filings/0000080420-26-000107.md) |
| Selling, general and administrative | $m | [20.4 d](/filings/0000080420-25-000152.md) | [20.3](/filings/0000080420-25-000029.md) | [20.9](/filings/0000080420-25-000061.md) | [22.0](/filings/0000080420-25-000098.md) | [21.6 d](/filings/0000080420-25-000152.md) | [21.5](/filings/0000080420-26-000015.md) | [21.8](/filings/0000080420-26-000070.md) | [25.1](/filings/0000080420-26-000107.md) | [27.0 d](/filings/0000080420-25-000152.md) | [25.2](/filings/0000080420-26-000015.md) | [25.8](/filings/0000080420-26-000070.md) | [26.7](/filings/0000080420-26-000107.md) |
| Operating income | $m | [29.8 d](/filings/0000080420-25-000152.md) | [25.9](/filings/0000080420-25-000029.md) | [39.5](/filings/0000080420-25-000061.md) | [57.3](/filings/0000080420-25-000098.md) | [56.1 d](/filings/0000080420-25-000152.md) | [35.6](/filings/0000080420-26-000015.md) | [58.9](/filings/0000080420-26-000070.md) | [60.1](/filings/0000080420-26-000107.md) | [63.2 d](/filings/0000080420-25-000152.md) | [42.8](/filings/0000080420-26-000015.md) | [57.6](/filings/0000080420-26-000070.md) | [64.1](/filings/0000080420-26-000107.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [6.3 d](/filings/0000080420-25-000152.md) | [5.8](/filings/0000080420-25-000029.md) | [10.4](/filings/0000080420-25-000061.md) | [15.6](/filings/0000080420-25-000098.md) | [14.4 d](/filings/0000080420-25-000152.md) | [4.7](/filings/0000080420-26-000015.md) | [16.1](/filings/0000080420-26-000070.md) | [15.9](/filings/0000080420-26-000107.md) | [16.1 d](/filings/0000080420-25-000152.md) | [5.6](/filings/0000080420-26-000015.md) | [15.9](/filings/0000080420-26-000070.md) | [17.0](/filings/0000080420-26-000107.md) |
| Net income | $m | [26.4](/filings/0000080420-24-000086.md) | [24.1](/filings/0000080420-25-000152.md) | [33.5](/filings/0000080420-25-000152.md) | [46.2](/filings/0000080420-25-000152.md) | [46.1](/filings/0000080420-25-000152.md) | [34.8](/filings/0000080420-26-000107.md) | [46.3](/filings/0000080420-26-000107.md) | [48.2](/filings/0000080420-26-000107.md) | [51.4](/filings/0000080420-25-000152.md) | [41.4](/filings/0000080420-26-000107.md) | [45.9](/filings/0000080420-26-000107.md) | [52.2](/filings/0000080420-26-000107.md) |
| Diluted EPS | $ per share | [2.17](/filings/0000080420-24-000086.md) | [1.98](/filings/0000080420-25-000152.md) | [2.75](/filings/0000080420-25-000152.md) | [3.79](/filings/0000080420-25-000152.md) | [3.77](/filings/0000080420-25-000152.md) | [2.86](/filings/0000080420-26-000015.md) | [1.27](/filings/0000080420-26-000070.md) | [1.32](/filings/0000080420-26-000107.md) | [4.22](/filings/0000080420-25-000152.md) | [3.40](/filings/0000080420-26-000015.md) | [1.25](/filings/0000080420-26-000070.md) | [1.42](/filings/0000080420-26-000107.md) |
| Basic EPS | $ per share | [2.22](/filings/0000080420-24-000086.md) | [2.02](/filings/0000080420-25-000152.md) | [2.79](/filings/0000080420-25-000152.md) | [3.85](/filings/0000080420-25-000152.md) | [3.84](/filings/0000080420-25-000152.md) | [2.89](/filings/0000080420-26-000015.md) | [1.28](/filings/0000080420-26-000070.md) | [1.33](/filings/0000080420-26-000107.md) | [4.26](/filings/0000080420-25-000152.md) | [3.42](/filings/0000080420-26-000015.md) | [1.26](/filings/0000080420-26-000070.md) | [1.43](/filings/0000080420-26-000107.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [246](/filings/0000080420-24-000086.md) | [321](/filings/0000080420-24-000008.md) | [323](/filings/0000080420-24-000030.md) | [332](/filings/0000080420-24-000059.md) | [315](/filings/0000080420-25-000152.md) | [326](/filings/0000080420-25-000029.md) | [360](/filings/0000080420-25-000061.md) | [398](/filings/0000080420-25-000098.md) | [451](/filings/0000080420-26-000107.md) | [491](/filings/0000080420-26-000015.md) | [538](/filings/0000080420-26-000070.md) | [634](/filings/0000080420-26-000107.md) |
| Current assets | $m | [622](/filings/0000080420-24-000086.md) | [675](/filings/0000080420-24-000008.md) | [717](/filings/0000080420-24-000030.md) | [736](/filings/0000080420-24-000059.md) | [776](/filings/0000080420-25-000152.md) | [762](/filings/0000080420-25-000029.md) | [811](/filings/0000080420-25-000061.md) | [880](/filings/0000080420-25-000098.md) | [932](/filings/0000080420-26-000107.md) | [920](/filings/0000080420-26-000015.md) | [1,008](/filings/0000080420-26-000070.md) | [1,231](/filings/0000080420-26-000107.md) |
| Total assets | $m | [752](/filings/0000080420-24-000086.md) | [808](/filings/0000080420-24-000008.md) | [850](/filings/0000080420-24-000030.md) | [869](/filings/0000080420-24-000059.md) | [928](/filings/0000080420-25-000152.md) | [913](/filings/0000080420-25-000029.md) | [965](/filings/0000080420-25-000061.md) | [1,042](/filings/0000080420-25-000098.md) | [1,109](/filings/0000080420-26-000107.md) | [1,094](/filings/0000080420-26-000015.md) | [1,180](/filings/0000080420-26-000070.md) | [1,407](/filings/0000080420-26-000107.md) |
| Current liabilities | $m | [396](/filings/0000080420-24-000086.md) | [428](/filings/0000080420-24-000008.md) | [442](/filings/0000080420-24-000030.md) | [418](/filings/0000080420-24-000059.md) | [428](/filings/0000080420-25-000152.md) | [397](/filings/0000080420-25-000029.md) | [405](/filings/0000080420-25-000061.md) | [427](/filings/0000080420-25-000098.md) | [446](/filings/0000080420-26-000107.md) | [402](/filings/0000080420-26-000015.md) | [447](/filings/0000080420-26-000070.md) | [625](/filings/0000080420-26-000107.md) |
| Total liabilities | $m | [407](/filings/0000080420-24-000086.md) | [442](/filings/0000080420-24-000008.md) | [456](/filings/0000080420-24-000030.md) | [432](/filings/0000080420-24-000059.md) | [445](/filings/0000080420-25-000152.md) | [416](/filings/0000080420-25-000029.md) | [424](/filings/0000080420-25-000061.md) | [447](/filings/0000080420-25-000098.md) | [468](/filings/0000080420-26-000107.md) | [425](/filings/0000080420-26-000015.md) | [471](/filings/0000080420-26-000070.md) | [651](/filings/0000080420-26-000107.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [345](/filings/0000080420-25-000152.md) | [366](/filings/0000080420-25-000098.md) | [394](/filings/0000080420-25-000098.md) | [437](/filings/0000080420-25-000098.md) | [483](/filings/0000080420-26-000107.md) | [496](/filings/0000080420-26-000107.md) | [541](/filings/0000080420-26-000107.md) | [595](/filings/0000080420-26-000107.md) | [641](/filings/0000080420-26-000107.md) | [669](/filings/0000080420-26-000107.md) | [709](/filings/0000080420-26-000107.md) | [756](/filings/0000080420-26-000107.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [77.2 d](/filings/0000080420-25-000152.md) | [83.9](/filings/0000080420-25-000029.md) | [17.0 d](/filings/0000080420-25-000061.md) | [13.8 d](/filings/0000080420-25-000098.md) | [(6.0) d](/filings/0000080420-25-000152.md) | [37.1](/filings/0000080420-26-000015.md) | [22.4 d](/filings/0000080420-26-000070.md) | [47.4 d](/filings/0000080420-26-000107.md) | [61.1 d](/filings/0000080420-25-000152.md) | [43.6](/filings/0000080420-26-000015.md) | [51.2 d](/filings/0000080420-26-000070.md) | [100 d](/filings/0000080420-26-000107.md) |
| Capital expenditure | $m | [3.8 d](/filings/0000080420-25-000152.md) | [1.2](/filings/0000080420-25-000029.md) | [0.9 d](/filings/0000080420-25-000061.md) | [1.4 d](/filings/0000080420-25-000098.md) | [8.5 d](/filings/0000080420-25-000152.md) | [2.2](/filings/0000080420-26-000015.md) | [4.1 d](/filings/0000080420-26-000070.md) | [5.1 d](/filings/0000080420-26-000107.md) | [1.8 d](/filings/0000080420-25-000152.md) | [2.0](/filings/0000080420-26-000015.md) | [1.8 d](/filings/0000080420-26-000070.md) | [6.5 d](/filings/0000080420-26-000107.md) |
| Dividends paid | $m | [3.1 d](/filings/0000080420-25-000152.md) | [3.1](/filings/0000080420-25-000029.md) | [3.2 d](/filings/0000080420-25-000061.md) | [3.2 d](/filings/0000080420-25-000098.md) | [3.2 d](/filings/0000080420-25-000152.md) | [3.2](/filings/0000080420-26-000015.md) | [3.2 d](/filings/0000080420-26-000070.md) | [3.2 d](/filings/0000080420-26-000107.md) | [3.2 d](/filings/0000080420-25-000152.md) | [3.2](/filings/0000080420-26-000015.md) | [3.3 d](/filings/0000080420-26-000070.md) | [3.3 d](/filings/0000080420-26-000107.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: not reported

## Shares

| Line item | Unit | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [12.1](/filings/0000080420-24-000008.md) | [12.1](/filings/0000080420-24-000030.md) | [12.1](/filings/0000080420-24-000059.md) | [12.2](/filings/0000080420-25-000029.md) | [12.2](/filings/0000080420-25-000061.md) | [12.2](/filings/0000080420-25-000098.md) | [12.2](/filings/0000080420-26-000015.md) | [36.5](/filings/0000080420-26-000070.md) | [36.5](/filings/0000080420-26-000107.md) | [12.2](/filings/0000080420-26-000015.md) | [36.6](/filings/0000080420-26-000070.md) | [36.6](/filings/0000080420-26-000107.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 36,432,564 at 2026-08-03, from the cover of the [10-Q filed 2026-08-04](/filings/0000080420-26-000107.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:20 ET. No prices; not investment advice.